Detalhe da pesquisa
1.
Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.
N Engl J Med
; 389(1): 33-44, 2023 Jul 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37407001
2.
Sustained remissions in CLL after frontline FCR treatment with very-long-term follow-up.
Blood
; 142(21): 1784-1788, 2023 11 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-37595283
3.
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.
Lancet
; 402(10402): 641-654, 2023 08 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37295445
4.
Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL.
Blood
; 139(12): 1794-1806, 2022 03 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34699592
5.
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.
Blood
; 139(22): 3278-3289, 2022 06 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35196370
6.
Global miRNA profiling reveals key molecules that contribute to different chronic lymphocytic leukemia incidences in Asian and Western populations.
Haematologica
; 109(2): 479-492, 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646669
7.
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024.
J Natl Compr Canc Netw
; 22(3): 175-204, 2024 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38626800
8.
STAT3 Activates the Pentraxin 3 Gene in Chronic Lymphocytic Leukemia Cells.
J Immunol
; 208(12): 2847-2855, 2022 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35595309
9.
Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity.
Cancer
; 129(14): 2192-2200, 2023 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37016930
10.
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.
N Engl J Med
; 382(6): 545-553, 2020 02 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32023374
11.
Acalabrutinib in treatment-naive chronic lymphocytic leukemia.
Blood
; 137(24): 3327-3338, 2021 06 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-33786588
12.
KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results.
Blood
; 138(1): 11-22, 2021 07 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33827116
13.
Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results.
Am J Hematol
; 98(3): 493-501, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36600670
14.
Prognostication of DNA Damage Response Protein Expression Patterns in Chronic Lymphocytic Leukemia.
Int J Mol Sci
; 24(6)2023 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36982555
15.
Reverse Phase Protein Array Profiling Identifies Recurrent Protein Expression Patterns of DNA Damage-Related Proteins across Acute and Chronic Leukemia: Samples from Adults and the Children's Oncology Group.
Int J Mol Sci
; 24(6)2023 Mar 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36982537
16.
The cure of leukemia through the optimist's prism.
Cancer
; 128(2): 240-259, 2022 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34614211
17.
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.
Lancet
; 398(10299): 491-502, 2021 08 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34097852
18.
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
Lancet
; 397(10277): 892-901, 2021 03 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33676628
19.
Ibrutinib and Venetoclax for First-Line Treatment of CLL.
N Engl J Med
; 380(22): 2095-2103, 2019 05 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31141631
20.
How I manage CLL with venetoclax-based treatments.
Blood
; 135(17): 1421-1427, 2020 04 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-32076705